2015
DOI: 10.1007/s11095-015-1637-y
|View full text |Cite
|
Sign up to set email alerts
|

Isolation and Characterization of Acetylated Derivative of Recombinant Insulin Lispro Produced in Escherichia coli

Abstract: PurposeInsulin lispro is a rapid-acting insulin analogue produced by recombinant DNA technology. As a biosynthetic drug, the protein undergoes strict monitoring aiming for detection and characterization of impurities. The goal of this study was to isolate and identify a derivative of insulin lispro formed during biosynthesis.MethodsFor this purpose, ion exchange chromatography in combination with endoproteinase Glu-C digestion, MALDI-TOF/TOF mass spectrometry and Edman sequencing were employed.ResultsIon excha… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 38 publications
(34 reference statements)
0
5
0
Order By: Relevance
“…Each acetylated isoform of a recombinant protein has the potential to have different biological implications. To reduce the number of acetylated isoforms, excess carbon should be avoided (21), and the growth medium should be buffered and supplemented with magnesium.…”
Section: Discussionmentioning
confidence: 99%
“…Each acetylated isoform of a recombinant protein has the potential to have different biological implications. To reduce the number of acetylated isoforms, excess carbon should be avoided (21), and the growth medium should be buffered and supplemented with magnesium.…”
Section: Discussionmentioning
confidence: 99%
“…Finally, researchers should remember that heterologous expression of a protein in E. coli or any other bacterium carries the possibility that the purified protein preparation may be a heterogeneous mixture decorated by various acylations. Indeed, at least one group has reported that recombinant insulin produced in E. coli is acetylated (Szewczak et al, 2015). The potential for acylations to influence efficacy has great implications for the pharmaceutical industry, but also for any researcher who uses a heterologous system to express their protein of interest.…”
Section: Future Thoughtsmentioning
confidence: 99%
“…Lysine acetylation has been detected following production in E. coli of recombinant therapeutic proteins, including the chemokine RANTES (d'Alayer et al, 2007), human basic fibroblast growth factor mutein (Suenaga et al, 1996), human carbonic anhydrase (Mahon et al, 2015), insulin lispro (Szewczak et al, 2015), interleukin-10 (Pflumm et al, 1997), interleukin-2 (Moya et al, 2002), interferon alpha (Takao et al, 1987), neurotropin-3 (Ross et al, 1996), and somatotropin (Violand et al, 1994). Nearly 30% of currently approved recombinant therapeutic proteins are produced in E. coli (Huang et al, 2012).…”
Section: Consequences For Pharmaceutical Productionmentioning
confidence: 99%